Market Currents

• Tuesday, December 22, 2009

• 10:23 AM Winners in the Senate healthcare reform:
  - Drug and device makers (PFE, MRK, BSX, MDT)
  - Hospitals (UHS, THC)
  - Biologics (AMGN)
  - Cosmetics (JNJ, AGN)
  - Home healthcare providers (AMED, ADUS, GTIV)
  Losers:
  - Health insurers (WLP, UNH, AET)
  - Generic drugmakers
  - Pharmacy benefit managers (MHS, CVS, ESRX)
  - Nursing homes (SKH, KND) 13 Comments

• Thursday, October 29, 2009

• 09:06 AM Allergan (AGN): Q3 EPS of $0.70 in-line. Revenue of $1.13B (+4.2%) vs. $1.08B. Shares +0.8% premarket. (PR) Comment!
• 00:05 AM Notable pre-market earnings: ABX, AEP, AET, AGN, AN, APA, AVP, AYE, AZN, BC, BCRX, BKC, BPO, CL, CLI, CME, CMS, COCO, COT, DLR, EK, EXPE, FNFG, GTI, K, KBR, MCO, MOT, MPS, MWW, MYL, NBL, NEM, NRG, ODP, OMX, PCG, PDE, PG, PPL, PTEN, RDS.A, S, SII, TSM, VTR, WMB, XEL, XOM Comment!

• Friday, July 31, 2009

• 09:14 AM Allergan (AGN): Q2 EPS of $0.75 beats by $0.08. Revenue of $1.13B (-3.5%) in-line. Shares +0.8% premarket. Sees Q3 EPS of $0.67-0.69 vs. $0.72. (PR) Comment!
• 00:05 AM Notable earnings before Friday's open: AEP, AGN, AIV, AN, CEG, CVX, D, ITT, PEG, PKD, SRE, TOT, WY Comment!

• Tuesday, June 16, 2009

• 09:49 AM Sanofi-Aventis (SNY +1.6%) may be on the prowl for a mega pharma deal. Obvious targets include Bristol-Myers (BMY) and Amgen (AMGN), but smaller fry like Allergan (AGN) and Biogen Idec (BIIB) would be easier for SNY to digest without impairing its investment-grade credit rating. Comment!

• Wednesday, May 27, 2009

• 09:58 AM FDA tells Allergan (AGN -1%) it needs more info about Botox before approving it to treat post-stroke spasticity of the upper limbs, but doesn't ask for new trials. Analysts say the news - which could delay approval for 8-9 months - is disappointing, but doesn't hamper the long-term outlook. Comment!

• Friday, May 1, 2009

• 09:10 AM Allergan (AGN): Q1 EPS of $0.55 beats by $0.02. Revenue of $1.01B (-6.4%) in-line. Q2 and full-year guidance in-line. Shares -1.4% premarket. (PR) Comment!
• 00:05 AM Notable earnings before Friday's open: AEE, AGN, AIV, AOC, AXL, BPO, CLX, CVX, DF, ED, FLIR, FO, JRCC, LPNT, MA, NI, PPL, SPG, TE Comment!

• Tuesday, March 24, 2009

• 13:15 PM S&P leaders at midday: ACAS +32.5%. IP +12.7%. AGN +10.9%. MTG +10.3%. HSP +8.4%. PFG +7.7%. MS +8%. X +7.8%. ASH +8.1%. JDSU +7.1%. Laggards: DYN -11.8%. HBAN -8.6%. MKC -8%. CME -6.7%. NWL -6.8%. MTB -6.2% Comment!

• Wednesday, February 4, 2009

• 09:07 AM Allergan (AGN): Q4 EPS of $0.76 beats by $0.03. Revenue of $1.06B (-3.1%) vs. $1.04B. Shares -5.0% premarket. (PR) Comment!
• 00:05 AM Notable earnings before Wednesday's open: AGN, ALU, ARM, CLX, DVN, FNF, GR, ITT, KFT, NI, NOV, PM, PPL, R, RL, SLE, TMO, TWC, TWX, WIN Comment!

• Wednesday, January 14, 2009

• 15:42 PM Love the Long Eyelashes. Who’s Your Doctor? Allergan (AGN) plans to introduce Latisse, the first FDA-approved drug for growing longer eyelashes, later this month. Will the not-so-rich and vain really shell out $120/month for eye candy? 1 Comment

• Wednesday, December 24, 2008

• 07:23 AM At Mattel (MAT), plans for a new, edgier Barbie. MAT hopes Barbie 2.0 will appeal to the tweens, and goose sales which have been flat for five of the past seven years. At 49, maybe they should consider Botox (AGN). Comment!

• Monday, December 1, 2008

• 11:42 AM Johnson & Johnson (JNJ -3%) proves high-premium buyouts are rare but not altogether dead with its near-100%-premium acquisition of breast-implant maker Mentor (MNT +89.4%). Counter-trade: Sell Allergan (AGN -8.3%). Comment!

• Wednesday, October 29, 2008

• 12:32 PM Trading higher on strong earnings: LM +31%. HERO +28%. MGM +32%. NXY +20%. ANR +20%. SU +16%. AG +14%. NBL +14%. HES +10%. SPR +9%. VPHM +8% PX +7%. OC +6%. ODP +6%. AGN +5%. GRMN +4%. Comment!